Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults
Mpox Neutralizing Antibody Response to LC16m8 VaccineIn this study of 50 healthy volunteers in Japan, a smallpox vaccine (LC16m8) exhibited a robust neutralizing antibody response against two strains of the mpox virus. With a 94% "take" rate by day 14, seroconversion rates on day 28 were 72 and 70% against the Zr599 and Liberia strains, respectively, decreasing to 30% for both on day 168; no serious adverse events occurred.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
NEJM evidence - 3(2024), 3 vom: 01. Feb., Seite EVIDoa2300290 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morino, Eriko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 28.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1056/EVIDoa2300290 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36901412X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36901412X | ||
| 003 | DE-627 | ||
| 005 | 20240229171256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/EVIDoa2300290 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM36901412X | ||
| 035 | |a (NLM)38411447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morino, Eriko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Mpox Neutralizing Antibody Response to LC16m8 VaccineIn this study of 50 healthy volunteers in Japan, a smallpox vaccine (LC16m8) exhibited a robust neutralizing antibody response against two strains of the mpox virus. With a 94% "take" rate by day 14, seroconversion rates on day 28 were 72 and 70% against the Zr599 and Liberia strains, respectively, decreasing to 30% for both on day 168; no serious adverse events occurred | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Smallpox Vaccine |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 700 | 1 | |a Mine, Sohtaro |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Uemura, Yukari |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Okumura, Nobumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Haruka |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Ainai, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Eunsil |e verfasserin |4 aut | |
| 700 | 1 | |a Seki, Sayuri |e verfasserin |4 aut | |
| 700 | 1 | |a Akazawa, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Shimojima, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shiwa-Sudo, Nozomi |e verfasserin |4 aut | |
| 700 | 1 | |a Virhuez-Mendoza, Milagros |e verfasserin |4 aut | |
| 700 | 1 | |a Miyauchi, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Moriyama, Saya |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata-Yoshikawa, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Michiko |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Shigeyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hishiki, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kotaki, Ryutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumura, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Kanno, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Isogawa, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Watashi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nagata, Noriyo |e verfasserin |4 aut | |
| 700 | 1 | |a Ebihara, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Yoshimasa |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Matano, Tetsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Wakita, Takaji |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Tadaki |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiura, Wataru |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmagari, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Ujiie, Mugen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NEJM evidence |d 2022 |g 3(2024), 3 vom: 01. Feb., Seite EVIDoa2300290 |w (DE-627)NLM339641495 |x 2766-5526 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:EVIDoa2300290 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/EVIDoa2300290 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2024 |e 3 |b 01 |c 02 |h EVIDoa2300290 | ||